Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope

Journal of Immunotherapy

Volumn 28, Issue 4, 2005, Pages 352-358

  Kallinteris, Nikoletta L ^a   Wu, Shuzhen ^a   Lu, Xueqing ^a   Humphreys, Robert E ^a   Von Hofe, Eric ^a   Xu, Minzhen ^a  

^a Antigen Express Inc   (United States)

Author keywords

gp100; Ii Key; Melanoma; MHC class II; T helper cell; Vaccine

Indexed keywords

CARBENE; CD4 ANTIGEN; EPITOPE; FUNCTIONAL GROUP; GAMMA INTERFERON; GLYCOPROTEIN 100[48-58]; GLYCOPROTEIN GP 100; HLA DR4 ANTIGEN; HYBRID PROTEIN; II KEY PROTEIN; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; PEPTIDE DERIVATIVE; POLYMER; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG POTENCY; ENGINEERING; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SYNTHESIS; T LYMPHOCYTE; TRANSGENIC MOUSE; VACCINATION;

EID: 21844447116     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000170362.45456.00     Document Type: Article

References (39)

1. Reyes VE, Lu S, Humphreys RE. Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains. J Immunol. 1991;146:3877-3880.
2. Xu M, Capraro GA, Daibata M, et al. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol. 1994;31:723-731.
3. Daibata M, Xu M, Humphreys RE, et al. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. Mol Immunol. 1994;31:255-260.
4. Reyes VE, Daibata M, Espejo R, et al. Invariant chain dissociation from class II MHC is a catalyst for foreign peptide binding. Ann N Y Acad Sci. 1994;730:338-341.
5. Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol. 1995;25:1693-1702.
6. Adams S, Albericio F, Alsina J, et al. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittelforschung. 1997;47:1069-1077.
7. Xu M, Jackson R, Adams S, et al. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung. 1999;49:791-799.
8. Humphreys RE, Adams S, Koldzic G, et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine. 2000;18:2693-2697.
9. Kallinteris NL, Lu X, Wu S, et al. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine. 2003;21:4128-4132.
10. Gillogly ME, Kallinteris NL, Xu M, et al. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother. 2004;53:490-496.
11. Xu M, Li J, Gulfo JV, et al. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol. 2001;54:39-44.
12. Sant'Angelo DB, Robinson E, Janeway CA Jr, et al. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur J Immunol. 2002;32:2510-2520.
13. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675.
14. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
15. Surman DR, Dudley ME, Overwijk WW, et al. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000;164:562-565.
16. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
17. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
18. Touloukian CE, Leitner WW, Topalian SL, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000;164:3535-3542.
19. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001;61:7577-7584.
20. Cochlovius B, Stassar M, Christ O, et al. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol. 2000;15:4731-4741.
21. Kierstead LS, Ranieri E, Olson W, et al. Gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells. Br J Cancer. 2001;85:1738-1745.
22. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer. 1998;75:517-524.
23. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458-6462.
24. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I and class II-restricted peptides from melanoma associated antigens. J Immunother. 2003;26:349-356.
25. Ito K, Bian HJ, Molina M, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med. 1996;183:2635-2644.
26. Hesse MD, Karulin AY, Boehm BO, et al. A T cell clone's avidity is a function of its activation state. J Immunol. 2001;67:1353-1361.
27. Anthony DD, Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods. 2003;29:260-269.
28. Lee J, Chuang TH, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA. 2003;100:6646-6651.
29. Yip HC, Karulin AY, Tary-Lehmann M, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol. 1999;162:3942-3949.
30. Karulin AY, Hesse MD, Tary-Lehmann M, et al. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol. 2000;15:1862-1872.
31. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505-514.
32. Liu N, Ohnishi N, Ni L, et al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol. 2003;4:687-693.
33. Kumar S, Jones TR, Oakley MS, et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun. 2004;72:949-957.
34. Yang S, Linette GP, Longerich S, et al. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol. 2002;169:531-539.
35. Parkhurst MR, DePan C, Riley JP, et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol. 2003;170:5317-5325.
36. Paczesny S, Banchereau J, Wittkowski KM, et al. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med. 2004;199:1503-1511.
37. Liao X, Li Y, Bonini C, et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004;9:757-764.
38. Rakhmilevich AL, Imboden M, Hao Z, et al. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 2001;7:952-961.
39. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.